This project of 7.9 billion yen should in particular contribute to dé tracking of breast, stomach, esophagus, lung, liver, v dé gall bladder, the pancr dé as, the c & OCIRC ; lon, ovarian, prostate and bladder.
It could also help & agrave ; dé detect pr dé cocement pathologies dé g é n é ; operatives including Alzheimer’s disease.
This is v dé rifier pr dé presence in the blood of micro- acids ribonucl dé ic, whose increase is assumed dé e report dé development of cancer.
Over 2500 varieties dé t dé these mol s dé particles have dé t & eacute; recens dé are in the human body and could serve as & quot; Markers & quot; for dé detect diff dé ferent types of cancers, m dé method much faster than existing tests sometimes heavy batteries today.
Several dé research teams in Europe and the United States int dé also feels r & OCIRC, the microRNA in cases of various cancers, but researchers Japanese esp & egrave ; rent to advance further in their investigations, which does however still pending & agrave ; r dé realization of a commercial test.
The program is men & eacute; by the Japanese Organization news dé energies and industrial technologies which supports programs for large-scale research in various fields, with the participation of several companies including Toray Industries and Toshiba has big ambitions in the field m dé dical.
This project will build on the data dé are 65 000 patients provided by the National Cancer Center.
& quot; If we can & agrave ; dé velopper the world’s leading test of high pr dé decision in Japan, this may extend to several years dé ‘re the hard dé e of people’s lives and contribute to dé development of Japanese industries & quot ;, has ensured dé Tomomitsu Hotta, pr dé president of the center, cit dé by Kyodo agency.
According to the World Health Organisation é ;, cancer is a major cause of mortality dé Worldwide, & agrave ; Originally 8.2 million dé c & egrave, s in 2012.